A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics

Vranić, Semir; Bender, R. Joseph; Palazzo, Juan; Gatalica, Zoran

doi:10.1016/j.humpath.2012.01.002

Cited by 46 publications

(29 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent reviews on mammary AdCC, as well as the latest version of the WHO classification of tumors of the breast, state that the myoepithelial/basal cells of AdCC are immunoreactive for basal cytokeratins (CK5, CK5/6, CK14, CK17), myoepithelial markers (p63, actin, calponin, S100 protein), vimentin, and epidermal growth factor receptor (EGFR) [4,7,17]. We found, however, that S100 is not useful as a marker for myoepithelial cells in AdCC and that CK5/6-positive cells in AdCC are more frequently around true AdCC lumina, indicating that CK5/6 is a marker for luminal rather than abluminal cells in AdCC (Figs.…”

Section: Discussionmentioning

confidence: 99%

The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers

et al. 2016

View full text Add to dashboard Cite

Adenoid cystic carcinoma (AdCC) of the breast is an uncommon but distinct neoplasm composed of a dual cell population polarized around true glandular (luminal) spaces and pseudolumina. The aim of this study was to clarify whether various immunohistochemical markers (CK7, EMA, CD117, p63, calponin, CD10, S100, CK5/6, CK14, vimentin, and type IV collagen) can distinguish between the two cell types in classical AdCC (n = 14) and in collagenous spherulosis (n = 5). The sensitivity and specificity of these 11 markers to distinguish luminal from abluminal cells were evaluated using a curve created by plotting the true-positive rate (sensitivity) against the false-positive rate (1 - specificity) at threshold settings of 0, 10, 50, and 70 %. The most sensitive and specific markers for luminal cells in AdCC were CK7 and EMA; those for abluminal cells were type IV collagen, p63, and vimentin. CD10 and S100 did not act as abluminal markers in AdCC. CK5/6, one of the basal/myoepithelial markers, was expressed more frequently in luminal than in abluminal cells of AdCC. Thus, CK5/6 immunostaining resulted in a reverse expression pattern, analogous to what we recently documented in clear cells in mammary adenomyoepithelioma. In conclusion, compared with myoepithelial/abluminal cells of normal breast or collagenous spherulosis, the neoplastic abluminal cells of classical AdCC are characterized by enhanced vimentin and attenuated CD10 and S100. Furthermore, the luminal cells of AdCC show a unique aberrant staining pattern for CK5/6 that may aid in the differential diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The former showed indolent clinical behavior, and the latter showed an aggressive course. Adenoid cystic carcinoma of breast presents as a localized disease with a low frequency of axillary lymph node involvement of less than 8%, and rare distant metastases of fewer than 20% [27–30]. Therefore, most clinicians recommend a breast-conserving surgical therapy with or without radiotherapy [31].…”

Section: Discussionmentioning

confidence: 99%

Malignant adenomyoepithelioma combined with adenoid cystic carcinoma of the breast: a case report and literature review

Yang

Wang

et al. 2014

Diagn Pathol

View full text Add to dashboard Cite

BackgroundMalignant adenomyoepithelioma and adenoid cystic carcinoma are both rare malignant epithelial-myoepithelial tumors of the breast. We report a very rare case with a malignant adenomyoepithelioma combining with adenoid cystic carcinoma in a single mass.Case presentationA 61-year-old female presented with a palpable painless mass in the right breast. Mammography revealed a large irregular dense shadow without obvious internal calcification. A simple lumpectomy was performed, and a 1.6cm well-circumscribed pale-tan nodule was presented. Histologically, the nodule was composed of two obscure lobules. One exhibited typical histological image of adenoid cystic carcinoma, the other one showed the image of epithelial-myoepithelial carcinoma of salivary gland, and support the diagnosis of biphasic malignant adenomyoepithelioma. Transition between the two lobules was gradual. Immunohistochemically, CK18 and P63 highlighted the epithelial and myoepithelial cells respectively in both lesions. CD117 was positive in the epithelial cells of adenoid cystic carcinoma, but was totally negative in malignant adenomyoepithelioma.ConclusionThis report is, to our knowledge, the first case that combines these two tumors in a single mass. In addition, we present a review of the literature. The histogenesis of these tumors is also discussed.Virtual SlidesThe virtual slide(s) for this article can be found here: http://med.motic.com/MoticGallery/Slide?id=D562817E-23C2-4F72-9823-86EF6DA40005&user=2C69F0D6-A478-4A2B-ABF0-BB36763E8025 and http://med.motic.com/MoticGallery/Slide?id=38BB7126-6FFB-4B66-A208-B8C0F528DCA8&user=2C69F0D6-A478-4A2B-ABF0-BB36763E8025

show abstract

“…Adenoid cystic carcinoma of the breast is very rare, accounting for less than 1% of breast cancers. Adenoid cystic carcinoma predominantly affects postmenopausal women, with a median age at diagnosis of 60 years [37]. Morphologically, these tumors are similar to adenoid cystic carcinomas arising in the salivary glands, showing epithelial cells and myoepithelial cells arranged in tubular and cribriform architecture.…”

Section: Typically Hormone Receptor Negativementioning

confidence: 97%

Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities

et al. 2014

View full text Add to dashboard Cite

Breast cancer encompasses a collection of different diseases characterized by different biological and pathological features, clinical presentation, response to treatments, clinical behavior, and outcome. On the basis of cell morphology, growth, and architecture patterns, breast cancer can be classified in up to 21 distinct histological types. Breast cancer special types, including the classic lobular invasive carcinoma, represent 25% of all breast cancers. The histological diversity of breast carcinomas has relevant prognostic implications. Indeed, the rare breast cancer group includes subtypes with very different prognoses, ranging from the tubular carcinoma, associated with an indolent clinical course, to metaplastic cancer, whose outcome is generally unfavorable. New approaches based on gene expression profiling allow the identification of molecularly defined breast cancer classes, with distinct biological features and clinical behavior. In clinical practice, immunohistochemical classification based on the expression of human epidermal growth factor receptor 2 and Ki67 is applied as a surrogate of the intrinsic molecular subtypes. However, the identification of intrinsic molecular subtypes were almost completely limited to the study of ductal invasive breast cancer. Moreover, some goodprognosis triple-negative histotypes, on the basis of gene expression profiling, can be classified among the poorprognosis group. Therefore, histopathological classification remains a crucial component of breast cancer diagnosis. Special histologies can be very rare, and the majority of information on outcome and treatments derives from small series and case reports. As a consequence, clear recommendations about clinical management are still lacking. In this review, we summarize current knowledge about rare breast cancer histologies. The Oncologist 2014;19:805-813 Implications for Practice: Breast cancer special histologies encompass a panel of various entities with peculiar clinical behaviors. The rarity of such histotypes has jeopardized an extensive clinical evaluation. A review of current available data may help physicians in their clinical practice; however, the development of clear clinical recommendations is not possible. Decisions on the management of patients with rare breast cancer histologies should derive from careful case-by-case multidisciplinary evaluations.

show abstract

A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics

Cited by 46 publications

References 83 publications

The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers

The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers

Malignant adenomyoepithelioma combined with adenoid cystic carcinoma of the breast: a case report and literature review

Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities

Contact Info

Product

Resources

About